Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug DiscoveryArup K. Ghose, John P. Mallamo, Torsten Herbertz et al.|ACS Chemical Neuroscience|2011Cited by 436
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.Bruce Ruggeri, Craig A. Dionne, Роберто Пили et al.|PubMed|2003Cited by 124
Neurotrophic 3,9-Bis[(alkylthio)methyl]- and -Bis(alkoxymethyl)-K-252a DerivativesMasami Kaneko, Chikara Murakata, Yutaka Saito et al.|Journal of Medicinal Chemistry|1997Cited by 120
A New Class of Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Structure−Activity Relationships for a Series of 9-Alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazole-5-ones and the Identification of CEP-5214 and Its Dimethylglycine Ester Prodrug Clinical Candidate CEP-7055Diane E. Gingrich, Robert L. Hudkins, D. Rajagopala Reddy et al.|Journal of Medicinal Chemistry|2003Cited by 74
Discovery and Characterization of 6-{4-[3-(<i>R</i>)-2-Methylpyrrolidin-1-yl)propoxy]phenyl}-2<i>H</i>-pyridazin-3-one (CEP-26401, Irdabisant): A Potent, Selective Histamine H<sub>3</sub>Receptor Inverse AgonistRobert L. Hudkins, Michael Williams, Rita Raddatz et al.|Journal of Medicinal Chemistry|2011Cited by 68